undamentalytics Newsletter
Sign in

Tela Bio, Inc. (TELA) stock

Add to watchlist

Add holding +

NASDAQ: TELA Nasdaq Health Care Equipment Next results ~November 10, 2026

D Fundamentals grade

Tela Bio, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$2.4

Forward price-to-sales vs peers

Base case. Range ~$2.4–$8.9. Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Tela Bio, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders3 buying, 0 selling7 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds21 adding, 11 cuttingOf 3 active managers that changed their stake, 2 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Tela Bio files

Where Tela Bio stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $80m, up 6.1% on a year earlier, slower than the 13.5% growth a quarter earlier. Free-cash-flow margin rose to -39.6% from -46.0% a year earlier. Operating margin widened to -42.6% from -49.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 5 financial-health checks. Our price-to-sales vs peers value is $1.36 a share, against a share price of $0.97.

Source: 10-Q filed August 11, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Tela Bio, Inc.'s trailing-twelve-month revenue grew 6.1% year on year, with a free-cash-flow margin of -39.6%. Where it lags: long-term debt as % of assets of 93.9% ranks 87 of 87 health care equipment companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 6.1% (-7.4pp vs the prior quarter), the 2nd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 6.9 points on a year ago.

Things to watch

  • Results due soon. Results are expected around 10 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 7.4 points lower than a quarter earlier.
  • Loss-making. Operating margin is -42.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -39.6% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 14.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 94% and a beta of 1.1 against the S&P 500.

Latest results: FY2026 Q2

Filed August 11, 2026
Earnings per share
-$0.20 against an average estimate of -$0.18: missed by 12.4%
Revenue
$19m, down 4.5% on a year earlier
Share reaction
-9.2% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Next report
November 10, 2026; average EPS estimate -$0.16

Tela Bio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.6%
  • 1 week-18.1%
  • 1 month-31.0%
  • This year-32.3%
  • 1 year-42.6%
  • 5 years-93.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$79.9M
Operating margin
-42.6%
Net margin
-51.5%
EPS (TTM, diluted)
$-0.78

Growth

Revenue growth
+6.1%
Change in growth rate
−7.4 pts

Cash

Free cash flow (TTM)
-$31.6M
FCF margin
-39.6%
Stock pay % of revenue
4.0%

Earnings

Last results
August 10, 2026
Next results (est.)
November 10, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Announcement
  3. Announcement
  4. Agreement
  5. Leadership
  6. Results
  7. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Tela Bio, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Tela Bio, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.09 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: the projected cash flows don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.4 ~$2.7–$8.9 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$2.4 ~$2.4–$8.9 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Tela Bio, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$12.95$15.04$12.80$11.50$6.62$3.02$1.18$0.80
Market value$23m$195m$185m$187m$151m$86m$55m$42m
+ Net debt (− = net cash)−$15m−$44m−$12m−$2m−$6m−$12m$5m$26m
Enterprise value$8m$151m$173m$185m$145m$75m$60m$68m
Multiples
Price / sales 1.5x10.7x6.3x4.5x2.6x1.2x0.7x0.5x
Price / earnings ————————
Price / free cash flow ————————
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

34 /100

Weak moat

How hard Tela Bio's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -39.3% of total assets over 7 years.

  • Pricing power 17 / 20

    Gross margin has been a median 65.4%, moving by 4.6 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -91.6%; its worst year was -155.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 7 years, at a median -85.6% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, after the close. Analysts expect revenue of $20m and EPS of −$0.16 (range −$0.21 to −$0.13) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.70 +16% $80m −1%
Next −$0.45 +35% $86m +9%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.8% on 90 days ago. In the last 30 days, 1 analyst raised Tela Bio, Inc.'s forecast and 4 cut it.

Consensus EPS forecast Tela Bio, Inc., last 90 days
−$0.80 −$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.67 Current fiscal year, 60 days ago: −$0.70 Current fiscal year, 30 days ago: −$0.69 Current fiscal year, 7 days ago: −$0.69 Current fiscal year, Now: −$0.70 −$0.70 Next fiscal year, 90 days ago: −$0.56 Next fiscal year, 60 days ago: −$0.52 Next fiscal year, 30 days ago: −$0.46 Next fiscal year, 7 days ago: −$0.45 Next fiscal year, Now: −$0.45 −$0.45

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.67−$0.56
60 days ago −$0.70−$0.52
30 days ago −$0.69−$0.46
7 days ago −$0.69−$0.45
Now −$0.70−$0.45

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.18 −$0.20 −12.4%
Dec 2025 −$0.18 −$0.17 +6.6%
Sept 2025 −$0.20 −$0.19 +5.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Oct 2026415
  2. Sep 20261416
  3. Aug 20261315

Counts of recommendations published by analysts covering Tela Bio, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.0%
of tradable shares
Days to cover
2.85
at average volume
Short interest, 1 month
+16%
to October 15, 2026
Held by institutions
63%
of shares
Held by insiders
7.2%
of shares
Employees
218
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
TELA−15%−10%−42%−54%−61%−32%
Industry peers (median)−7%−37%−8%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
TELA42%58%33%33%33%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
TELA−32%−60%−63%−70%−71%−53%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 8, 2019: 98% from June 19, 2020 to April 13, 2026. Getting back needed a 3938% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.56 – $1.41
From 52-week high
−43.3%
vs 50-day average
−21.0%
vs 200-day average
−6.6%
Volatility (1 year)
94%
Beta vs S&P 500
1.08

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±13.7%
After a week
5 up, 7 down
typical move ±17.9%
After a month
6 up, 6 down
typical move ±22.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −9.2% −0.3% −25.3% +4.7%
May 12, 2026 −1.0% +0.4% −11.3% −6.0%
April 30, 2026 +15.0% +1.3% +27.9% +4.7%
March 24, 2026 −16.9% +0.2% −25.3% −25.1%
November 13, 2025 −12.4% −1.7% −7.0% −0.9%
August 11, 2025 −7.0% +0.9% −1.2% −8.7%
May 8, 2025 +13.7% +0.6% +3.2% +95.8%
March 20, 2025 −37.7% −0.3% −41.9% −62.3%
November 7, 2024 +1.8% +1.2% +0.7% +0.3%
October 22, 2024 +5.6% −1.0% +14.3% +15.5%
August 12, 2024 −23.9% +1.7% −24.4% −35.0%
May 9, 2024 +20.2% +0.7% +32.5% +15.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Tela Bio, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Tela Bio, Inc.
$50M $60M $70M $80M $90M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $53.1M Revenue (TTM), FY23 Q4: $58.5M Revenue (TTM), FY24 Q1: $63.1M Revenue (TTM), FY24 Q2: $64.7M Revenue (TTM), FY24 Q3: $68.6M Revenue (TTM), FY24 Q4: $69.3M Revenue (TTM), FY25 Q1: $71.2M Revenue (TTM), FY25 Q2: $75.3M Revenue (TTM), FY25 Q3: $77.1M Revenue (TTM), FY25 Q4: $80.3M Revenue (TTM), FY26 Q1: $80.8M Revenue (TTM), FY26 Q2: $79.9M $79.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $53.1M
FY23 Q4 $58.5M
FY24 Q1 $63.1M
FY24 Q2 $64.7M
FY24 Q3 $68.6M
FY24 Q4 $69.3M
FY25 Q1 $71.2M
FY25 Q2 $75.3M
FY25 Q3 $77.1M
FY25 Q4 $80.3M
FY26 Q1 $80.8M
FY26 Q2 $79.9M
Revenue growth, TTM YoY Tela Bio, Inc.
0% 20% 40% 60% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 39.1% Revenue growth, TTM YoY, FY23 Q4: 41.1% Revenue growth, TTM YoY, FY24 Q1: 40.0% Revenue growth, TTM YoY, FY24 Q2: 31.6% Revenue growth, TTM YoY, FY24 Q3: 29.3% Revenue growth, TTM YoY, FY24 Q4: 18.6% Revenue growth, TTM YoY, FY25 Q1: 12.8% Revenue growth, TTM YoY, FY25 Q2: 16.3% Revenue growth, TTM YoY, FY25 Q3: 12.2% Revenue growth, TTM YoY, FY25 Q4: 15.8% Revenue growth, TTM YoY, FY26 Q1: 13.5% Revenue growth, TTM YoY, FY26 Q2: 6.1% 6.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 39.1%
FY23 Q4 41.1%
FY24 Q1 40.0%
FY24 Q2 31.6%
FY24 Q3 29.3%
FY24 Q4 18.6%
FY25 Q1 12.8%
FY25 Q2 16.3%
FY25 Q3 12.2%
FY25 Q4 15.8%
FY26 Q1 13.5%
FY26 Q2 6.1%
Operating margin (TTM) Tela Bio, Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -77.7% Operating margin (TTM), FY23 Q4: -75.4% Operating margin (TTM), FY24 Q1: -59.6% Operating margin (TTM), FY24 Q2: -60.0% Operating margin (TTM), FY24 Q3: -55.4% Operating margin (TTM), FY24 Q4: -49.2% Operating margin (TTM), FY25 Q1: -55.8% Operating margin (TTM), FY25 Q2: -49.5% Operating margin (TTM), FY25 Q3: -46.0% Operating margin (TTM), FY25 Q4: -42.0% Operating margin (TTM), FY26 Q1: -41.8% Operating margin (TTM), FY26 Q2: -42.6% -42.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -77.7%
FY23 Q4 -75.4%
FY24 Q1 -59.6%
FY24 Q2 -60.0%
FY24 Q3 -55.4%
FY24 Q4 -49.2%
FY25 Q1 -55.8%
FY25 Q2 -49.5%
FY25 Q3 -46.0%
FY25 Q4 -42.0%
FY26 Q1 -41.8%
FY26 Q2 -42.6%
FCF margin (TTM) Tela Bio, Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -77.7% FCF margin (TTM), FY23 Q4: -70.9% FCF margin (TTM), FY24 Q1: -70.4% FCF margin (TTM), FY24 Q2: -68.0% FCF margin (TTM), FY24 Q3: -67.1% FCF margin (TTM), FY24 Q4: -61.4% FCF margin (TTM), FY25 Q1: -52.9% FCF margin (TTM), FY25 Q2: -46.0% FCF margin (TTM), FY25 Q3: -40.9% FCF margin (TTM), FY25 Q4: -35.7% FCF margin (TTM), FY26 Q1: -37.4% FCF margin (TTM), FY26 Q2: -39.6% -39.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -77.7%
FY23 Q4 -70.9%
FY24 Q1 -70.4%
FY24 Q2 -68.0%
FY24 Q3 -67.1%
FY24 Q4 -61.4%
FY25 Q1 -52.9%
FY25 Q2 -46.0%
FY25 Q3 -40.9%
FY25 Q4 -35.7%
FY26 Q1 -37.4%
FY26 Q2 -39.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 4 8 15 18 29 41 58 69 80 80
Gross profit 3 3 9 11 19 27 40 46 54 54
EBITDA −16 −17 −19 −25 −29 −39 −44 −33 −33 −33
Operating income −17 −18 −19 −25 −29 −39 −44 −34 −34 −34
Net income −21 −21 −22 −29 −33 −44 −47 −38 −39 −41
Diluted EPS — −$101.41 −$17.10 −$2.23 −$2.30 −$2.72 −$2.04 −$1.33 −$0.83 −$0.78
Growth (year on year)
Revenue — +94.9% +86.7% +17.9% +61.8% +40.6% +41.1% +18.6% +15.8% +6.1%
Margins
Gross margin 59.6% 35.6% 60.0% 61.7% 63.9% 65.3% 68.6% 67.1% 67.7% 67.8%
EBITDA margin −380.8% −209.3% −122.3% −137.6% −99.2% −93.3% −74.7% −48.3% −41.3% −41.8%
Operating margin −398.7% −214.9% −124.1% −138.8% −100.0% −94.2% −75.4% −49.2% −42.0% −42.6%
Net margin −502.6% −254.9% −145.2% −158.1% −112.9% −106.9% −79.8% −54.6% −48.4% −51.5%
Free-cash-flow margin −388.3% −241.6% −166.5% −135.2% −105.4% −100.5% −70.9% −61.4% −35.7% −39.6%
Cash flow
Cash from operations −16 −20 −26 −24 −30 −41 −41 −42 −28 −31
Capital spending 0 0 0 0 1 1 1 1 0 0
Free cash flow −16 −20 −26 −25 −31 −42 −41 −43 −29 −32
Stock-based pay 0 0 0 2 4 4 5 4 4 3
Free cash flow after stock pay −17 −20 −26 −27 −35 −46 −47 −47 −32 −35
Balance sheet
Cash 11 17 45 74 44 42 47 53 51 30
Total debt 0 0 30 31 31 40 41 41 56 56
Net debt (negative = net cash) −11 −17 −15 −44 −12 −2 −6 −12 5 26
Diluted shares — — 2m 13m 14m 16m 23m 29m 47m 53m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 5 checks passed · June 30, 2026
What it owns · $60m
Short-term assets $54mLonger-term assets $5m
What it owes, and who funded it · $76m
Short-term liabilities $18mLonger-term liabilities $57mShareholders' equity $-16m
  • Short-term assets cover short-term liabilities $54m of assets due within a year against $18m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $54m short-term assets against $57m of longer-dated liabilities.
  • More cash than debt $30m of cash against $56m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$31m of operating cash flow against $56m of debt.
  • Operating profit covers interest at least five times over Operating income of −$34m against $7m of interest.

From Tela Bio, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
11.9%
of revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated TELA PDEX SGHT RCEL ELMD LUNG Median
Revenue, last 12 months $80m $80m $83m $76m $74m $87m $99m
Revenue growth, last 12 months 6.1% 13.3% 9.3% 1.0% 15.3% −3.4% 9.2%
Revenue growth, 3-year average 17.6% 19.2% 0.8% 22.8% 15.4% 13.0% 13.5%
Revenue growth, latest quarter −4.5% 11.0% 19.5% 17.8% 11.6% −4.6% 10.2%
Gross margin 67.8% 32.5% 88.0% 81.6% 78.5% 77.1% 61.2%
Operating margin −42.6% 16.8% −33.4% −46.6% 18.8% −53.0% −8.5%
Operating margin, 3-year average −50.7% 15.6% −54.2% −69.8% 15.3% −64.4% −17.9%
Net margin −51.5% 15.1% −35.7% −57.0% 15.3% −55.0% −12.0%
Cash from operations / revenue −39.0% 14.4% −27.9% −32.0% 13.1% −34.9% −1.9%
Free-cash-flow margin −39.6% 13.4% −28.0% −32.5% 11.3% −35.1% −3.9%
Free-cash-flow margin, 3-year average −51.2% 2.2% −34.5% −65.3% 14.8% −39.2% −7.0%
Stock pay / revenue 4.0% 0.8% 12.9% 9.6% 3.7% 19.7% 6.1%
Change in share count 14.4% −1.8% 4.7% 14.7% −2.5% 4.7% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 6.1% 9.1% 77 of 129
Change in growth rate Growth -7.4pp -0.6pp 106 of 129
Gross margin Profitability 67.8% 61.9% 48 of 123
Operating margin Profitability -42.6% -8.3% 85 of 132
Net margin Profitability -51.5% -12.0% 89 of 133
Free-cash-flow margin Cash generation -39.6% -3.4% 91 of 128
Stock pay as % of revenue Cash generation 4.0% 6.1% 52 of 123
Long-term debt as % of assets Balance sheet 93.9% 24.2% 87 of 87

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$23.7M
Institutions reporting
44
Shares held vs prior quarter
▲ 17.7%
Positions opened / closed
10 / 1

Top buyers and sellers, Q2 2026: 21 institutions bought and 11 sold ; the biggest buyer was Nantahala Capital Management, LLC (+6.6M shares) and the biggest seller UBS Group AG (−1.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Nantahala Capital Management, LLC $8.8M 11.8M 37.2% ▲ 129.2%
Essex Woodlands Management, Inc. $5.8M 7.7M 24.4% 0.0%
Stonepine Capital Management, LLC $2M 2.7M 8.4% ▲ 1.7%
Silverarc Capital Management, LLC $1.6M 2.1M 6.8% ▼ 5.4%
Vanguard Capital Management LLC $1.2M 1.6M 5.0% ▲ 1.8%
Dafna Capital Management LLC $1.1M 1.4M 4.6% 0.0%
Perkins Capital Management Inc $1M 1.4M 4.3% ▼ 3.1%
Sio Capital Management, LLC $477,225 636K 2.0% 0.0%
Wealthtrust Axiom LLC $343,300 458K 1.4% ▲ 21.4%
Geode Capital Management, LLC $291,952 389K 1.2% ▼ 14.5%
Blackrock, Inc. $280,887 375K 1.2% ▼ 19.6%
Vanguard Fiduciary Trust Co $159,854 213K 0.7% ▲ 0.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Tela Bio, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $4.2M 7 trades by 3 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $4.2M net buying
Insider Date Trade Shares Price Value
Capper Joseph H Director September 17, 2026 Buy 25,000 $1.22 $30,500
Capper Joseph H Director September 16, 2026 Buy 50,000 $1.17 $58,500
Capper Joseph H Director September 15, 2026 Buy 50,000 $1.06 $53,000
Capper Joseph H Director September 14, 2026 Buy 25,000 $1.02 $25,500
Getz Heather C Chief Executive Officer August 17, 2026 Buy 12,500 $0.66 $8,250
Getz Heather C Chief Executive Officer August 14, 2026 Buy 15,000 $0.70 $10,500
Ew Healthcare Partners Fund 2-Ugp, Llc 10% owner November 17, 2025 Buy 3,604,000 $1.11 $4M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 10, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 12, 2026
  • April 30, 2026
  • March 24, 2026
  • November 13, 2025
  • August 11, 2025

Recent SEC filings

Data status

When each part of this page on Tela Bio, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Tela Bio, Inc. in brief

What does Tela Bio, Inc. do?
Tela Bio, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Tela Bio, Inc.'s stock ticker?
Tela Bio, Inc. trades under the ticker TELA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Tela Bio, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Tela Bio, Inc. reported revenue of $79.9M, 6.1% higher than a year earlier, according to its SEC filings.
What is Tela Bio, Inc.'s free cash flow?
Tela Bio, Inc.'s free-cash-flow margin is -39.6% of revenue over the trailing twelve months, ranking 91 of the 128 health care equipment companies we cover.
Who are Tela Bio, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Nantahala Capital Management, LLC, Essex Woodlands Management, Inc. and Stonepine Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Tela Bio, Inc.'s market cap?
On November 2, 2026, Tela Bio, Inc.'s market capitalisation was about $42.3M and net debt of $25.7M. Market figures come from third-party market data and may be delayed.
Who are Tela Bio, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Tela Bio, Inc. are PRO DEX Inc, Sight Sciences, Inc., Avita Medical, Inc., Electromed, Inc. and Pulmonx Corp. The side-by-side comparison below sets their revenue, margins and growth against Tela Bio, Inc.'s.
Are insiders buying or selling Tela Bio, Inc. stock?
Over the last 12 months, Tela Bio, Inc.'s directors and officers reported 7 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Tela Bio, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Tela Bio, Inc. announces its own schedule.